Evidence map›Paper›PMID 29984474›Full record

ArticlePharmaceutical statistics2018

A proposal for a new PhD level curriculum on quantitative methods for drug development.

T Jaki, A Gordon, P Forster, L Bijnens, B Bornkamp, W Brannath, R Fontana, M Gasparini, L V Hampson, T Jacobs and 6 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutical statistics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Training the next generation of pharmacometric modelers: a multisector perspective.Journal of pharmacokinetics and pharmacodynamics · 2024
    Article
  2. Article
  3. Why do you need a biostatistician?BMC medical research methodology · 2020
    Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 8 institutions in 7 countries.

T JakiLancaster University, Department of Mathematics and Statistics, Lancaster, UK.ORCID 0000-0002-1096-188X
A GordonLancaster University, Department of Mathematics and Statistics, Lancaster, UK.
P ForsterLancaster University, Department of Mathematics and Statistics, Lancaster, UK.
L BijnensJanssen Pharmaceutica NV, Beerse, Belgium.
B BornkampNovartis Pharma AG, Basel, Switzerland.
W BrannathUniversity of Bremen, KKSB and IfS Faculty 3 - Mathematics/Computer Science, Bremen, Germany.ORCID 0000-0002-8622-3904
R FontanaPolitecnico di Torino, Turin, Italy.
M GaspariniPolitecnico di Torino, Turin, Italy.
L V HampsonNovartis Pharma AG, Basel, Switzerland.
T JacobsJanssen Pharmaceutica NV, Beerse, Belgium.
B JonesNovartis Pharma AG, Basel, Switzerland.
X PaolettiINSERM CESP-OncoStat Institut Gustave Roussy & Université Paris-Saclay UVSQ & Service de Biostatistique et d'Epidémiologie, Gustave Roussy, Villejuif, France.
M PoschMedical University of Vienna, Center for Medical Statistics, Informatics, and Intelligent Systems, Vienna, Austria.
A TitmanLancaster University, Department of Mathematics and Statistics, Lancaster, UK.
R VonkBayer AG, Berlin, Germany.
F KoenigMedical University of Vienna, Center for Medical Statistics, Informatics, and Intelligent Systems, Vienna, Austria.ORCID 0000-0002-6893-3304
Lancaster University · GBNovartis (Switzerland) · CHJanssen (Belgium) · BEPolitecnico di Torino · ITStatistics Austria · ATBayer (Germany) · DEInserm · FRUniversity of Bremen · DE

Funding

EU Horizon 2020 Marie-Curie ITN 633567Swiss State Secretariat for Education, Research, and Innovation (SERI) 999754557
6 · The paper itself

Abstract

This paper provides an overview of "Improving Design, Evaluation and Analysis of early drug development Studies" (IDEAS), a European Commission-funded network bringing together leading academic institutions and small- to large-sized pharmaceutical companies to train a cohort of graduate-level medical statisticians. The network is composed of a diverse mix of public and private sector partners spread across Europe, which will host 14 early-stage researchers for 36 months. IDEAS training activities are composed of a well-rounded mixture of specialist methodological components and generic transferable skills. Particular attention is paid to fostering collaborations between researchers and supervisors, which span academia and the private sector. Within this paper, we review existing medical statistics programmes (MSc and PhD) and highlight the training they provide on skills relevant to drug development. Motivated by this review and our experiences with the IDEAS project, we propose a concept for a joint, harmonised European PhD programme to train statisticians in quantitative methods for drug development.

Indexed as

Cooperative BehaviorCurriculumDrug DevelopmentDrug IndustryEducation, GraduateEuropeHumansPrivate SectorPublic SectorResearchStatistics as Topicdevelopment of early-stage researchersdrug developmentPhD curriculumregulatory statisticsuniversity-industry partnership

Identifiers

PMID29984474
PMCPMC6174936
OpenAlexW2811509240

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.